The products will treat osteoporosis and skeletal-related events from certain types of bone cancer, expanding the company's ...

Stephanie Draker, a Family Nurse Practitioner with Novant Health's Clemmons clinic, joins to discuss the causes and treatment ...

Our fat tissue could be used to make our bones regrow, with scientists successfully using adipose cells to repair spinal ...

Treatments for postmenopausal osteoporosis were generally misaligned with current guidelines among women at very high risk for fracture.

Osvyrti and Jubereq are FDA-approved denosumab biosimilars for osteoporosis and cancer-related skeletal events, ...

The FDA has approved Osvyrti (denosumab-desu), a biosimilar to Prolia (denosumab), and Jubereq (denosumab-desu), a biosimilar to Xgeva (denosumab).

Significant relationship between vagus nerve and bone remodeling was identified through artificial intelligence (AI)-based ...

Over half the women deemed very high risk are receiving treatment with therapies not recommended as first-line.

DelveInsight's Osteoporosis Market Insights report includes a comprehensive understanding of current treatment practices, osteoporosis emerging drugs, market share of individual therapies, and current ...

Premenopausal women and men with endocrine- or medication-related risks for osteoporosis may be affected, and timely bone ...

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at ...

Researchers developed a two-layer shell to encapsulate the estradiol hormone so it bypasses the uterus and releases only within an osteoporotic bone.